The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
    Coppock, Dagan
    Violet, Pierre-Christian
    Vasquez, Gustavo
    Belden, Katherine
    Foster, Michael
    Mullin, Bret
    Magee, Devon
    Mikell, Isabelle
    Shah, Lokesh
    Powers, Victoria
    Curcio, Brian
    Daskalakis, Constantine
    Monti, Daniel
    Levine, Mark
    LIFE-BASEL, 2022, 12 (03):
  • [12] The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID-19: A Randomized Controlled Clinical Trial
    Ahmadi, Sedigheh
    Mohit, Mohsen
    Mehrabi, Zeinab
    Heydari, Mohammad Reza
    Faraji, Seyed Nooreddin
    Yaghoubi, Shoeleh
    Zare, Morteza
    Masoumi, Seyed Jalil
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024 (01)
  • [13] Safety and Efficacy of Selenium on Recovery of Hospitalized Patients with COVID-19: A Randomized Controlled Clinical Trial
    Shafiei, Elham
    Mahmoudvand, Golnaz
    Rouzbahani, Arian Karimi
    Nazari, Ali
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2023, 18 (04):
  • [14] severe COVID-19 Patients: A Multicenter, Randomized, Open-Label Clinical Trial
    Trinh, Dieu-Thuong Thi
    Tran, An Hoa
    Bui, Minh-Man Pham
    Kieu, Thy Xuan
    Nguyen, Van -Dan
    Thuy, Nguyen Huu Lac
    Thai, Khac-Minh
    Vuong, Nguyen Lam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [15] Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy A Multicenter, Randomized Clinical Trial
    Johansson, Par, I
    Soe-Jensen, Peter
    Bestle, Morten H.
    Clausen, Niels E.
    Kristiansen, Klaus T.
    Lange, Theis
    Stensballe, Jakob
    Perner, Anders
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (03) : 324 - 329
  • [16] The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
    Kasiri, Hossein
    Ghazaiean, Mobin
    Rouhani, Nima
    Naderi-behdani, Fahimeh
    Ghazaeian, Monireh
    Ghodssi-Ghassemabadi, Robabeh
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (02) : 124 - 131
  • [17] Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial
    Trimarco, Valentina
    Izzo, Raffaele
    Lombardi, Angela
    Coppola, Antonietta
    Fiorentino, Giuseppe
    Santulli, Gaetano
    PHARMACOLOGICAL RESEARCH, 2023, 191
  • [18] Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
    Mohammadreza Moslemi
    Seyyedeh Mina Hejazian
    Molod Shaddelan
    Fatemeh Javanali
    Alireza Mirghaffari
    Armin Sadeghi
    Hamed Valizadeh
    Akbar Sharifi
    Morteza Haramshahi
    Mohammadreza Ardalan
    Sepideh Zununi Vahed
    Inflammopharmacology, 2022, 30 : 1277 - 1282
  • [19] Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
    Moslemi, Mohammadreza
    Hejazian, Seyyedeh Mina
    Shaddelan, Molod
    Javanali, Fatemeh
    Mirghaffari, Alireza
    Sadeghi, Armin
    Valizadeh, Hamed
    Sharifi, Akbar
    Haramshahi, Morteza
    Ardalan, Mohammadreza
    Vahed, Sepideh Zununi
    INFLAMMOPHARMACOLOGY, 2022, 30 (04) : 1277 - 1282
  • [20] Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial
    Zhuravel, Sergey, V
    Khmelnitskiy, Oleg K.
    Burlaka, Oleg O.
    Gritsan, Alexey, I
    Goloshchekin, Boris M.
    Kim, Seieun
    Hong, Ka Young
    ECLINICALMEDICINE, 2021, 41